ApidSOL™ Technology featured in a leading pharmaceutical journal

Topical tacrolimus skin penetration and ApidSOL™ technology probed for the first time by high spatial resolution X-ray microscopy technique is the subject of a peer-reviewed publication in the European Journal of Pharmaceutics and Biopharmaceutics. More information following this link.


ApidSOL™ Technology is the subject of a peer reviewed publication

New publication in the European Journal of Pharmaceutics and Biopharmaceutics is featuring ApidSOL™ technology and its delivery efficiency. Therapeutically relevant levels of Imiquimod (poorly soluble drug) in target tissue have been achieved with ApidSOL™ formulation despite a 100-fold dose reduction compared to a marketed product. More information here.


Apidel has been invited to the 32nd Seminar in pharmaceutical sciences in Zermatt

Prof Robert Gurny, CSO and co-founder of Apidel has been invited at the 32nd Seminar in pharmaceutical sciences in Zermatt on August 27 2018 to talk about “Disruptive technology for loco regional delivery of poorly soluble drugs”.


Apidel has received a granted patent from the USPTO

Apidel SA has the pleasure to announce that the patent application entitled "POLYLACTIDE COMPOSITIONS AND USES THEREOF" has been granted in the USA with the following patent number: US 9,925,267 B2.


Apidel at Advanced Functional Polymers for Medecine (AFMP) congress in Montpellier

Prof Robert Gurny, CSO and co-founder of Apidel is presenting ApidSOL™ micellar technology for improved local delivery at the Advanced Functional Polymers for Medecine (AFMP) congress at the University of Montpellier, France on May 16-18 2018.


ApidSOL™ technology featured at the 11th World Meeting on the Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

Dr Naoual Dahmana is presenting the results of the project featuring ApidSOL™ technology at the 11th World Meeting on the Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology on March 21 in Granada, Spain. Project title:  “Topical delivery of spironolactone nanocarriers prevents dexamethasone-induced delayed corneal wound healing”.


Polymer synthesis patent granted in Canada

Apidel SA has the pleasure to announced that the patent application related to the synthesis of its polymers "COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS" has been granted in Canada with the following patent number: 2,806,351


Our ApidSOL™ Technology is the subject of a peer reviewed publication

A new publication mentioning our ApidSOL™ Technology has been published in the journal “Experimental Eye Research”.
Kasper M. et al,  “Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis” (see https://www.ncbi.nlm.nih.gov/pubmed/29326066).


Apidel reinforces its IP position in European territories

Multiple patents have been granted to Apidel SA for the protection of their pharmaceutical compounds and uses. Apidel has the pleasure to announce today that its European patent EP1883665 “Polylactide Compositions And Uses Thereof” has been successfully validated in the following European territories: Denmark, Portugal, Great Britain and the Netherlands.


Apidel announces R&D collaboration with DNDi in the field of neglected disease

Apidel announces the signature of an agreement to collaborate with DNDi (Drugs for Neglected Diseases initiative) on the preclinical development of a topical treatment for Cutaneous Leishmaniasis, a neglected disease affecting between 0.7 to 1.2 million people worldwide. A promising drug candidate will be tested with Apidel’s proprietary drug delivery technology ApidSOL™. The press release is available here.